close-icon

Log In to Bolder Science

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

By completing and submitting this form, you agree to allow Bolder Science to collect the information provided and to receive communications from Bolder Science in the future regarding disease education and research updates.

close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 207 trials Clear all
Filter by:

Three Induction Treatments on Cryptococcal Meningitis

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Cryptococcal Meningitis, HIV/AIDS
    Cryptococcal Meningitis, HIV/AIDS
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: Voriconazole 200mg, Drug: amphotericin B deoxycholate (0.4-0.5mg/kg/d), Drug: Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Voriconazole 200mg, Drug: amphotericin B deoxycholate (0.4-0.5mg/kg/d), Drug: Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lijun Xu, Zhenjiang, Hangzhou, China

Brief Summary

Three induction treatment strategies [ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC ] for HIV-infected patients with cryptococcal meningitis were compared.

Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Traumatic Brain Injury
    Traumatic Brain Injury
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: Propranolol

Eligibility
  • Ages: 18 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Propranolol

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Faculty Of Medicine, Minya, Egypt

Brief Summary

evaluation of the effect of Propranolol versus propranolol and clonidine on decreasing sympathetic hyperactivity after moderate traumatic brain injury

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
    Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: Standard heparin dose, Drug: Real time heparin dose adjustment

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Standard heparin dose, Drug: Real time heparin dose adjustment

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Utah, Salt Lake City, Utah, United States

Brief Summary

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Healthy Volunteers
    Healthy Volunteers
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: SLN124, Drug: Placebo

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: SLN124, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hammersmith Medicines Research, London, United Kingdom

Brief Summary

This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Recurrent Head and Neck Carcinoma
    Recurrent Head and Neck Carcinoma
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Radiation: Brachytherapy, Drug: Cesium-131, Procedure: Conventional surgery

Eligibility
  • Ages: 18 to 90 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Radiation: Brachytherapy, Drug: Cesium-131, Procedure: Conventional surgery

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Brief Summary

This pilot clinical trial studies cesium Cs 131 brachytherapy in treating patients with head and neck cancer that has come back (recurrent) and can be removed by surgery. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Radioactive drugs, such as cesium Cs 131, may carry radiation directly to tumor cells and not harm normal cells. Permanently implanting cesium Cs 131 into the wound bed after surgery may help treat microscopic cancer cells that may be in the tissue after surgical removal of the tumor.

Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

This study is a single-center, open-label study of the plasma pharmacokinetics of amiloride nasal spray at three different doses in healthy volunteers.

Evaluation of PK and Safety of D-0120 and Allopurinol

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Healthy
    Healthy
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: D-0120 in combination with Allopurinol

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: D-0120 in combination with Allopurinol

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Spaulding Clinical, West Bend, Wisconsin, United States

Brief Summary

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

Angiotensin-(1-7) in Peripheral Arterial Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Not provided
    Not provided
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
INTERVENTION

Not provided

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

Peripheral arterial disease (PAD) affects over 8 million individuals in the United States alone. This is a form of atherosclerosis in which plaques preferentially build up inside the arteries of the legs to limit blood flow. These patients are at high risk for heart attack and stroke, with at least half dying from coronary artery disease. Our understanding of the causes of PAD remains incomplete. The renin-angiotensin hormone system is one mechanism known to contribute to atherosclerosis. Pharmacologic blockade of the hormone angiotensin II is beneficial in forms of atherosclerosis, including peripheral arterial disease, to improve blood vessel damage and functional outcomes. These therapies also increase circulating levels of angiotensin-(1-7), a hormone that dilates blood vessels. Angiotensin-(1-7) improves blood vessel function and reduces inflammation to protect against atherosclerosis in animal models; however, there are no clinical data in patients with atherosclerosis. The overall goal of this project is to examine the cardiovascular effects of angiotensin-(1-7) in PAD.

Lung Transplant HCV, Pilot Study

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Lung Transplant Infection, Hepatitis C
    Lung Transplant Infection, Hepatitis C
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: Sofosbuvir-velpatasvir (400 mg/100 mg), Device: Ex Vivo Lung Perfusion (EVLP)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Sofosbuvir-velpatasvir (400 mg/100 mg), Device: Ex Vivo Lung Perfusion (EVLP)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University Health Network Toronto General Hospital, Toronto, Ontario, Canada

Brief Summary

In this study HCV negative recipients will be transplanted with HCV positive lungs. Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus. Patients will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs. It is planned to enrolled 20 patients from the Lung transplant wait list in this study. Patients will be followed for 6 months. This will be a single center pilot study.

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Plasmacytoma, POEMS Syndrome
    Plasmacytoma, POEMS Syndrome
  • Phase Early Phase 1
    Early Phase 1
INTERVENTION

Drug: Dexamethasone, Drug: Ixazomib Citrate, Drug: Lenalidomide, Other: Questionnaire Administration

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Dexamethasone, Drug: Ixazomib Citrate, Drug: Lenalidomide, Other: Questionnaire Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Brief Summary

This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.